论文部分内容阅读
目的探讨盐酸氨溴索治疗慢性阻塞性肺疾病(COPD)的临床疗效及对患者肺功能与免疫功能的影响。方法选取2015年2—10月于福建省人民医院接受治疗的COPD患者80例,采用随机数字表法分为观察组与对照组,每组40例。两组患者均采用常规方法治疗,对照组给予布地奈德福莫特罗粉吸入剂(信必克都保)治疗,观察组联合盐酸氨溴索治疗,比较两组患者临床疗效、肺功能[最大呼气峰流速(PEF)、第一秒用力呼气量(FEV_1)、用力肺活量(FVC)]、免疫功能(CD3、CD4、CD8水平)及不良反应发生情况。结果观察组患者总有效率高于对照组,差异有统计学意义(P<0.05)。治疗前两组患者PEF、FEV_1、FVC比较,差异无统计学意义(P>0.05);治疗后观察组患者PEF、FEV_1、FVC高于对照组,差异有统计学意义(P<0.05)。治疗前两组患者CD3、CD4、CD8水平比较,差异无统计学意义(P>0.05);治疗后观察组患者CD3、CD4高于对照组,CD8水平低于对照组,差异有统计学意义(P<0.05)。治疗期间,两组患者均未发生明显的不良反应。结论盐酸氨溴索治疗COPD的临床疗效确切,可有效改善患者肺功能,提高免疫功能。
Objective To investigate the clinical efficacy of ambroxol hydrochloride in the treatment of chronic obstructive pulmonary disease (COPD) and its effect on lung function and immune function. Methods Eighty COPD patients treated in Fujian Provincial People’s Hospital from January to October in 2015 were divided into observation group and control group with 40 cases in each group by random number table. The patients in both groups were treated by conventional method. The control group was treated with budesonide formoterol powder inhalation (Xinbikudubao), the observation group was treated with ambroxol hydrochloride, and the clinical efficacy and pulmonary function were compared between the two groups PEF, FEV_1, FVC, immune function (CD3, CD4, CD8) and the occurrence of adverse reactions. Results The total effective rate of observation group was higher than that of control group, the difference was statistically significant (P <0.05). There was no significant difference in PEF, FEV_1 and FVC between the two groups before treatment (P> 0.05). After treatment, the PEF, FEV_1 and FVC in the observation group were higher than those in the control group, with significant difference (P <0.05). The levels of CD3, CD4 and CD8 in the two groups before treatment were not significantly different (P> 0.05). After treatment, the levels of CD3 and CD4 in the observation group were higher than those in the control group, and the level of CD8 was lower than that in the control group P <0.05). During treatment, no significant adverse reactions occurred in both groups. Conclusion Ambroxol Hydrochloride for the treatment of COPD is clinically effective and can effectively improve lung function and improve immune function.